Patents by Inventor Scott G. Filler
Scott G. Filler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220033777Abstract: Cell populations, compositions, and methods are provided relating to target priming of macrophage cells. The macrophages, once primed or activated with a microorganism, can be used to prevent or treat infection by the microorganism. Likewise, once primed or activated by a tumor cell or tumor antigen, the macrophage cell can be used to prevent or treat tumor of the same kind. The priming can be carried out in vitro or ex vivo. The macrophages can be isolated from the subject of disease prevention or treatment.Type: ApplicationFiled: September 17, 2019Publication date: February 3, 2022Inventors: Liana Chan, Scott G. Filler, Michael R. Yeaman
-
Patent number: 10857216Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.Type: GrantFiled: March 7, 2017Date of Patent: December 8, 2020Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Scott G. Filler, John P. Hennessey, Jr., Michael Timothy Cooke, Jack D. Sobel
-
Patent number: 10653757Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.Type: GrantFiled: July 20, 2012Date of Patent: May 19, 2020Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
-
Patent number: 10300120Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.Type: GrantFiled: February 3, 2016Date of Patent: May 28, 2019Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Ashraf S. Ibrahim, Bradley J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
-
Publication number: 20190076512Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.Type: ApplicationFiled: March 7, 2017Publication date: March 14, 2019Inventors: John E. EDWARDS, JR., Scott G. FILLER, John P. HENNESSEY, JR., Michael Timothy COOKE, Jack D. SOBEL
-
Publication number: 20190030141Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.Type: ApplicationFiled: October 11, 2018Publication date: January 31, 2019Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, JR., John P. Hennessey, JR.
-
Patent number: 10130691Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.Type: GrantFiled: March 14, 2014Date of Patent: November 20, 2018Assignees: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.Inventors: Ashraf S. Ibrahim, Michael R. Yeaman, Scott G. Filler, John E. Edwards, Jr., John P. Hennessey, Jr.
-
Publication number: 20170173153Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: ApplicationFiled: June 13, 2016Publication date: June 22, 2017Inventors: John E. EDWARDS, JR., Scott G. FILLER, Donald C. SHEPPARD, Ashraf S. IBRAHIM, Yue FU, Brad J. SPELLBERG
-
Publication number: 20160220648Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.Type: ApplicationFiled: February 3, 2016Publication date: August 4, 2016Inventors: John E. EDWARDS, Jr., Ashraf S. IBRAHIM, Brad J. SPELLBERG, Yue FU, Scott G. FILLER, Michael R. YEAMAN
-
Patent number: 9364539Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: GrantFiled: September 23, 2013Date of Patent: June 14, 2016Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
-
Publication number: 20160030533Abstract: The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of SEQ ID NOs: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of SEQ ID NOs: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 17. Additional polypeptides includes those of formula (I) [ZNZPVSSBSFSYT]n and formula (II) [ZNUWOOBUFOYT]n. The invention further features vaccines including such polypeptides or conjugates and methods of vaccination against candidiasis or a staphylococcal infection of both using same. In addition, the invention features antibodies that bind to the polypeptides or conjugates, and methods of passive immunization using same.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Michael R. YEAMAN, Ashraf S. IBRAHIM, Scott G. FILLER, John E. EDWARDS, JR.
-
Publication number: 20160030534Abstract: The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.Inventors: Ashraf S. IBRAHIM, Michael R. YEAMAN, Scott G. FILLER, John E. EDWARDS, JR., John P. HENNESSEY, JR.
-
Publication number: 20150273031Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.Type: ApplicationFiled: July 20, 2012Publication date: October 1, 2015Applicants: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, NovaDigm Therapeutics, Inc.Inventors: Michael R. Yeaman, John E. Edwards, JR., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, JR.
-
Publication number: 20140127217Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: ApplicationFiled: September 23, 2013Publication date: May 8, 2014Inventors: John E. Edwards, JR., Scott G. Filler, Danald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
-
Publication number: 20140127243Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: ApplicationFiled: September 23, 2013Publication date: May 8, 2014Inventors: John E. Edwards, JR., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
-
Publication number: 20140127218Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: ApplicationFiled: September 23, 2013Publication date: May 8, 2014Inventors: John E. Edwards, JR., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Brad J. Spellberg
-
Publication number: 20140037689Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue. The Als protein family member can be derived from a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis and the Als protein family member includes Als1p, Als3p, Als5p, Als6p, Als7p or Als9p. Also provided is a method of treating or preventing Staphylococcus aureus infections.Type: ApplicationFiled: March 5, 2013Publication date: February 6, 2014Inventors: John E. Edwards, JR., Ashraf S. Ibrahim, Brad J. Spellberg, Yue Fu, Scott G. Filler, Michael R. Yeaman
-
Patent number: 8541008Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: GrantFiled: September 13, 2002Date of Patent: September 24, 2013Assignee: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Bradley J. Spellberg
-
Publication number: 20120014995Abstract: The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated Als protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue.Type: ApplicationFiled: January 10, 2011Publication date: January 19, 2012Inventors: John E. Edwards, JR., Ashraf Ibrahim, Brad J. Spellberg, Yue Fu, Scott G. Filler, Michael Yeaman
-
Patent number: 7067138Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.Type: GrantFiled: November 18, 2000Date of Patent: June 27, 2006Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Bradley J. Spellberg